key: cord-0802550-1yby2x5j
authors: Grainger, Rebecca; Machado, Pedro M.; Robinson, Philip C.
title: Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology & outcomes
date: 2020-12-23
journal: Best Pract Res Clin Rheumatol
DOI: 10.1016/j.berh.2020.101657
sha: 9b1d5f763c929b6d411ff62d7767a7d65571da08
doc_id: 802550
cord_uid: 1yby2x5j

There is concern that people with rheumatic disease, often treated with immunosuppressive or immunomodulatory medication, may be at increased risk of poor outcomes of novel coronavirus disease-2019 (COVID-19). However, hyperinflammation is a major cause of morbidity and mortality in COVID-19 and treatment with glucocorticoids has been shown to improve outcomes in patients with severe COVID-19. Therefore, uncertainty exists about continuing or withholding immune therapies with risk of infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review covers the current knowledge with respect to risk of infection, and outcomes and risk factors for poor outcomes in patients with rheumatic disease. We also discuss data from other immune mediated diseases and its relevance to patients with rheumatic disease. In addition, we cover the limitations of the research efforts to date and how the current knowledge translates into practice guidance. Finally, we discuss our vision of the future research agenda.

Coronaviruses are a large family of ribonucleic acid (RNA) viruses with crown-like spikes on their surface that cause diseases in animals and humans. Most of the hundreds of coronaviruses circulate among animals (e.g., cats, pigs, camels and bats) but "spillover events" pneumonia, acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), thromboembolic events, multisystem inflammatory syndrome, multi-organ failure, and septic shock 1 . Many of the drugs being studied as potential treatments or preventive medications for COVID-19, such as interleukin (IL)-6 inhibitors, IL-1 inhibitors, anti-tumour necrosis factor inhibitors (anti-TNF), Janus Kinase (JAK) inhibitors, hydroxychloroquine and glucocorticoids 2 , are commonly used to treat rheumatic disease.

SARS-CoV-2 has precipitated extensive efforts to clarify the risk of poor outcomes in those with immune system disease, including people with rheumatic disease. Hypothetically, people with (inflammatory) rheumatic disease might have a different COVID-19 phenotype and may be at an increased risk of infection and/or severe COVID-19 for a number of reasons. These include;

underlying immune system dysfunction, treatment with immunomodulatory or immunosuppressive drugs, higher levels of comorbidity (e.g., cardiovascular disease and osteoporosis), and extra-articular manifestations of their rheumatic disease with organ vulnerability or dysfunction (e.g., kidney or lung involvement) 1 .

In this article we will review the epidemiology and outcomes of SARS-CoV-2 infection and COVID-19 in patients with rheumatic disease. We also discuss data from other immune mediated disease and its relevance to patients with rheumatic disease. In addition, we cover the limitations of the research efforts to date and how the current knowledge translates into practice guidance. Finally, we discuss what we believe the future research agenda should include.

The meta-prevalence of COVID-19 in autoimmune disease, including rheumatic disease, was recently estimated in a systematic review and meta-analysis 3 J o u r n a l P r e -p r o o f While these prevalence data are important and informative, it should be taken into account that the overall quality of evidence was only moderate due to significant study heterogeneity, namely sample size, diseases included, method of collection, diagnostic ascertainment, geographic location, and date of collection. Therefore, these data should be interpreted with caution.

J o u r n a l P r e -p r o o f

To date, most available data on outcomes for people with rheumatic disease infected with SARS-CoV-2 comes from single center or single country case series or from one large international registry; the COVID-19 Global Rheumatology Alliance (GRA) physician registry 11, 12 .

Case series have considerable limitations, discussed in detail below, however the data warrants consideration in terms of reassurance if outcomes do not appear substantially worse, and in terms of hypothesis generation and directing the focus of ongoing and future research 12 . The data from the GRA registry, given size, multiple sites with global data collection, will be discussed first.

The COVID-19 GRA physician registry resulted from a rapid collaborative effort of international rheumatologists with data collection launched on 24th March for the Global registry and on 27th

March for the European registry 12 . Preliminary data, on the first 110 patients, was published only three weeks later 13 with the analysis of the first 600 patients published two months after launch 14 . The registry allows rheumatology physicians to enter de-identified data about people with rheumatic disease and confirmed or highly probable COVID-19 infection in the global or European registries (to comply with data management regulations). Data includes patient and disease characteristics, comorbidities, rheumatic medications (cs/b/tsDMARDs), diagnosis, treatment and, when possible, outcomes of COVID-19 infection.

The case series reported by the GRA included 600 cases from 40 countries, although most were from the USA or European countries, entered between 24th March and 20th April 2020 14 .

This series represented people with more severe COVID-19 as nearly half (46%) were hospitalized and 9% (55) died. The cases were mostly female (71%) with median age of 56 years (interquartile range 45-67 years). The commonest rheumatic diseases included RA (38%), 

The following cohort studies include those with over 50 patients with rheumatic disease and a laboratory confirmed or highly suspected COVID-19 diagnosis.

A notable single center study conducted in Spain at the height of the first wave of COVID-19

infections in March/April 2020 also provides useful information about risks for hospitalization for COVID-19 in people with rheumatic disease 17 therapies. This is consistent with age as the major risk factor for death in general populations 22 .

The meta-analysis described above reporting meta-prevalence, also reported meta-analysis of outcomes of COVID-19 in patients with rheumatic conditions, including hospitalization and death 3 .01) associated with 5-aminosalicylates/sulfasalazine use 16 . There is biological plausibility for poor outcomes in COVID-19 with sulfasalazine use; in a virtual ligand screening study, sulfasalazine was identified as having high binding affinity for the SARS-CoV-2 spike protein and papain like protease 24 . Other computational screens have also predicted sulfasalazine as interacting with SARS-CoV-2 25, 26 . Sulfasalazine is used commonly in rheumatoid arthritis and peripheral spondyloarthritis and generally considered a drug with a good infectious side effect profile 27 . Further investigation of these results will be required in other datasets like the C19-GRA registry 28 .

The Emerging Infections Network (EIN) conducted a small observational study (n=81) in people with a range of immune mediated diseases from rheumatology, gastroenterology and multisystem diseases like sarcoidosis 29 . No patients on anti-TNF or Janus kinase inhibitors died (0/19, 0%) compared to those on other therapies (9/62, 15%). Initial positive reports on the J o u r n a l P r e -p r o o f efficacy of baricitinib in treating COVID-19, and reports on the potential of anti-TNF therapy are supported by these findings 30, 31 .

A large French study of 1,418 patients on treatments for psoriasis reported no COVID-19

deaths. Patients were using oral agents such as cyclosporine and methotrexate, as well as anti-TNF, anti-IL-17 and anti-IL-23 agents. Only 12 patients had PCR confirmed COVID-19 with an additional 54 having probable disease. Five patients were admitted, three of which went to ICU none died 32 .

A report of 76 patients with multiple sclerosis from New York with COVID-19 (both PCR confirmed and suspected) had a 24% hospitalisation rate and an 11% death rate. This cohort had 34 patients on B cell depleting agents and 5.8% of those patients died 33 . Although a very small report, a series of six patients on teriflunomide, which is the active metabolite of leflunomide, were reported from Lombardy in Italy. Patients all continued therapy throughout, and none of the patients required hospitalisation or ICU care 34 . The largest series of multiple sclerosis patients (n=347) was from France; 12 patients (3.5%) died and 73 patients (21%) were hospitalised. In multivariate analysis age, co-morbidity and disability status predicted poor COVID-19 outcomes, while there was no increased risk of poor outcomes with immunosuppressant use 35 .

The immediate impact of the pandemic meant that efforts to collect case data were urgent 36 .

could help address pressing questions. As such, data limitations, particularly bias and confounding are important to consider. Bias can be broadly thought of as information bias, selection bias and confounding. There are also the issues of confounding by indication and channeling bias when examining outcomes associated with drug exposures.

Information bias stems from errors in measurement, which is not likely to be a large issue for registry studies. Selection bias however is a major concern when considering voluntary registries. Selection bias arises from the non-random collection of data, such as in case reports and registries are particularly prone to selection bias. In this novel coronavirus pandemic, it is particularly relevant because often those who collect and report outcome data are hospitalbased and therefore, patient outcomes have the potential to be skewed to the more severe outcomes. This is likely evident in the results from the first report of the C19-GRA where 46% of patients were hospitalised and 9% died 14 J o u r n a l P r e -p r o o f

Hyper-inflammation seems to be a major contributor to the morbidity and mortality of COVID-19

and so there is likely to be an, as yet not clearly defined, role for therapies that suppress the immune system. This has been demonstrated in the outcomes of trial of glucocorticoids 46, 47 .

Due to the initial interest in anti-interleukin-6 therapies in the treatment of COVID-19, the ACR guidelines state that these therapies may be continued as part of a shared decision-making process. Advice to discontinue oral traditional csDMARDs except hydroxychloroquine or chloroquine seems prudent. The data on the effectiveness of IL-6 inhibitors in randomised trials has been largely disappointing 48 . Further knowledge derived from clinical trials of agents such as JAK inhibitors and anti-TNF may see these agents also be able to be continued as part of a shared decision making process however this awaits more definitive clinical trial outcome data 2 .

To date the rheumatology community has shown enormous commitment to collect data to There have also been numerous reports of prolonged symptoms after the acute illness of COVID-19 has settled, so called "Long-COVID" 51 . What this entity is and whether it is one or • The risk factors for poor outcome from general population of age and co-morbidity also apply to patients with rheumatic disease

• Some anti-rheumatic drugs like glucocorticoids may be associated with poorer outcomes but in the absence of known or suspected infection, it is recommended that antirheumatic therapy should be continued unchanged

• Entering patients with rheumatic disease who contract COVID-19 into an appropriate registry will help investigators better determine the drug-and disease-specific issues over time

• There is a need to study specific classes of medication for their individual risk profiles

• There is a need to study patients with individual rheumatic diseases to clarify whether there is differential risk between rheumatic diseases

• There is a need to study the safety and efficacy of vaccines directed at protecting from SARS-CoV-2 infection and adverse outcomes specifically in patients with rheumatic disease J o u r n a l P r e -p r o o f

RG reports non-financial support from Pfizer Australia, personal fees from Pfizer Australia, personal fees from Cornerstones, personal fees from Janssen New Zealand, non-financial support from Janssen Australia, personal fees from Novartis, outside the submitted work. PMM has received consulting/speaker's fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript. PCR reports personal fees from Abbvie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche and UCB, nonfinancial support from BMS, research funding from Janssen, Novartis, Pfizer and UCB, all outside the submitted work.

From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses

Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying antirheumatic drugs

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study

Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD

Susceptibility to COVID-19 in patients treated with antimalarials: a population based

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study

Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration

The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance

The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice

Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York

COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot

COVID-19 in patients with rheumatic diseases in northern Italy: a singlecentre observational and case-control study

Factors associated with COVID-19-related death using OpenSAFELY

IBD in the COVID-19 era: the value of international collaboration

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs

In-silico identification of potent inhibitors of COVID-19 main protease (Mpro) and angiotensin converting enzyme 2 (ACE2) from natural products: Quercetin, hispidulin, and cirsimaritin exhibited better potential inhibition than hydroxy-chloroquine against COVID-19 main protease active site and ACE2

DMARDS and infections in rheumatoid arthritis

The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic

SARS CoV-2 infection among patients using immunomodulatory therapies

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19

COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center

Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases

COVID-19 in patients with rheumatic diseases in northern Italy: a singlecentre observational and case-control study

COVID-19 in Rheumatic Diseases: A Research Agenda

Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic

Attitudes and Behaviours of Patients with Rheumatic Diseases during the early stages of the COVID-19 Outbreak

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Management of autoimmune disease during the COVID-19 pandemic

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv

SARS-CoV-2 vaccines in development

Developing Covid-19 Vaccines at Pandemic Speed

Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19